CytoSorbents Corporation (CTSO)

[cars100cars]

Superb growth without US sales...DebitsAndCredits, interesting 5 pillars. But the one bugaboo that reluctant investors point to is FDA approval yet to come. I think it is a mistake to make this a central focus of an investment thesis in CTSO. The US is only 330 million people. CTSO already serves populations over 2 billion. None of them care about the FDA's slow and stodgy approach to accept data from non-US studies. Gosh, the main purpose of the FDA Cardiac Surgery Pilot study was "safety." Duh! There had been 10,000 safe human treatments with CytoSorb before the pilot study began. Today, there are 20,000 safe human uses. When the FDA finally wakes up, it will be icing on the cake for us investors. Think about this. CTSO will likely have 2017 revenues of $20 million or more, with doubling again in 2018 to $40 million or more. Just one hospital in Germany is now ordering $1 million a year in CytoSorb units. None of this growth relies on FDA. Plus, Chan is in China today. Not one of the 3 billion people living in China cares about the FDA either. All these folks care about how CytoSorb saves lives, shortens ICU stays, and helps them get well again. And, as Germany has shown, insurance companies want docs using it because it saves medical payouts. Your fifth pillar should be the expansion of third-party payers throughout the world. This will significantly accelerate sales.